Novartis Issues Over $5 Billion in Notes
Ticker: NVSEF · Form: 6-K · Filed: Nov 5, 2025 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Nov 5, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $800,000,000, $700,000,000, $1,750,000,000, $925,000,000, $350,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, financing, notes
TL;DR
Novartis just dropped over $5B in new debt across multiple maturities.
AI Summary
Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of several tranches of notes on November 5, 2025. These include $800 million in Floating Rate Notes due 2028, $700 million in 3.900% Notes due 2028, $1.75 billion in 4.100% Notes due 2030, $925 million in 4.300% Notes due 2032, and $925 million in 4.600% Notes due 2035.
Why It Matters
This debt issuance indicates Novartis is raising significant capital, likely for operational needs, acquisitions, or refinancing existing debt, impacting its financial leverage and future investment capacity.
Risk Assessment
Risk Level: low — This is a routine debt issuance announcement by a large, established pharmaceutical company.
Key Numbers
- $5.15B — Total Notes Issued (Sum of all announced note issuances ($800M + $700M + $1.75B + $925M + $925M))
- 2028 — Maturity Year (Multiple note tranches mature in 2028)
- 2035 — Maturity Year (Longest maturity note tranche announced)
Key Players & Entities
- Novartis AG (company) — Registrant
- Novartis Capital Corporation (company) — Issuer of notes
- $800,000,000 (dollar_amount) — Principal amount of Floating Rate Notes
- $700,000,000 (dollar_amount) — Principal amount of 3.900% Notes due 2028
- $1,750,000,000 (dollar_amount) — Principal amount of 4.100% Notes due 2030
- $925,000,000 (dollar_amount) — Principal amount of 4.300% Notes due 2032
- $925,000,000 (dollar_amount) — Principal amount of 4.600% Notes due 2035
- November 5, 2025 (date) — Report date and issuance date
FAQ
What is the total aggregate principal amount of notes issued by Novartis Capital Corporation?
The total aggregate principal amount is $5,150,000,000, comprising $800 million in Floating Rate Notes, $700 million in 2028 Notes, $1.75 billion in 2030 Notes, $925 million in 2032 Notes, and $925 million in 2035 Notes.
What are the different types of notes issued and their respective amounts?
Novartis Capital Corporation issued $800,000,000 of Floating Rate Notes due 2028, $700,000,000 of 3.900% Notes due 2028, $1,750,000,000 of 4.100% Notes due 2030, $925,000,000 of 4.300% Notes due 2032, and $925,000,000 of 4.600% Notes due 2035.
When was this Form 6-K report filed?
This Form 6-K report was filed on November 5, 2025.
What is the primary business of Novartis AG?
Novartis AG is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
What is the address of Novartis AG's principal executive offices?
The address of Novartis AG's principal executive offices is Lichtstrasse 35, 4056 Basel, Switzerland.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2025-11-05 16:33:23
Key Financial Figures
- $800,000,000 — ance by Novartis Capital Corporation of $800,000,000 aggregate principal amount of Floating
- $700,000,000 — the “Floating Rate Notes”), $700,000,000 aggregate principal amount of 3.900% No
- $1,750,000,000 — ue 2028 (the “2028 Notes”), $1,750,000,000 aggregate principal amount of 4.100% No
- $925,000,000 — ue 2030 (the “2030 Notes”), $925,000,000 aggregate principal amount of 4.300% No
- $350,000,000 — ue 2035 (the “2035 Notes”), $350,000,000 aggregate principal amount of 5.200% No
- $550,000,000 — 2045 (the “2045 Notes”) and $550,000,000 aggregate principal amount of 5.300% du
Filing Documents
- tm2529850d5_6k.htm (6-K) — 15KB
- tm2529850d5_ex1-1.htm (EX-1.1) — 263KB
- tm2529850d5_ex4-1.htm (EX-4.1) — 99KB
- tm2529850d5_ex4-2.htm (EX-4.2) — 70KB
- tm2529850d5_ex4-3.htm (EX-4.3) — 73KB
- tm2529850d5_ex4-4.htm (EX-4.4) — 73KB
- tm2529850d5_ex4-5.htm (EX-4.5) — 73KB
- tm2529850d5_ex4-6.htm (EX-4.6) — 73KB
- tm2529850d5_ex4-7.htm (EX-4.7) — 84KB
- tm2529850d5_ex4-8.htm (EX-4.8) — 32KB
- tm2529850d5_ex5-1.htm (EX-5.1) — 16KB
- tm2529850d5_ex5-2.htm (EX-5.2) — 48KB
- tm2529850d5_ex1-1sp01img001.jpg (GRAPHIC) — 5KB
- tm2529850d5_ex4-1img001.jpg (GRAPHIC) — 5KB
- tm2529850d5_ex5-2img001.jpg (GRAPHIC) — 8KB
- 0001104659-25-107058.txt ( ) — 948KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 5, 2025 Novartis AG By: /s/ Daniel Weiss Name: Daniel Weiss Title: Authorized Signatory